SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Core Points - SELLAS Life Sciences hosted an R&D Day to discuss advancements and future directions in their research and development efforts [1][2] - The agenda included opening remarks by the CEO, followed by discussions on the AML treatment landscape and the company's product offerings [2][3] Group 1: Company Overview - The company is focused on addressing unmet needs in the treatment of Acute Myeloid Leukemia (AML) [2] - GPS and SLS009 are positioned within the current standards of care for AML [2] Group 2: Research and Development - Dr. Omer Jamy provided context on the AML treatment landscape, highlighting areas of unmet need [2] - Dr. Panagiotis Tsirigotis and Dr. Dragan Cicic discussed the mechanism of action and differentiation of GPS, along with details of the Phase III REGAL trial [3]